IRIDEX Corporation
1212 Terra Bella Avenue
Mountain View
California
94043
United States
Tel: 650-940-4700
Fax: 650-940-4710
Website: http://www.iridex.com/
Email: info@iridex.com
277 articles about IRIDEX Corporation
-
Iridex Announces Record Third Quarter 2022 Financial Results
11/10/2022
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, reported financial results for the third quarter ended October 1, 2022.
-
Iridex to Report Third Quarter 2022 Financial Results on November 10, 2022
10/27/2022
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 10, 2022.
-
Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022
9/29/2022
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, will showcase non-incisional glaucoma treatments, introduce its Sweep Management Software, and host 8 physician presentations at the 2022 American Academy of Ophthalmology annual meeting in Chicago, September 30 – October 3.
-
Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
8/18/2022
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.
-
Iridex Announces Second Quarter 2022 Financial Results
8/15/2022
Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022.
-
Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022
8/1/2022
Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2022 after the close of trading on Monday, August 15, 2022.
-
Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China
6/14/2022
Iridex Corporation announced that it has received regulatory clearance to market and sell its Cyclo G6® platform for the treatment of glaucoma diseases in China by its National Medical Products Administration.
-
Iridex Announces First Quarter 2022 Financial ResultsAchieved Record First Quarter Revenue
5/12/2022
Iridex Corporation reported financial results for the first quarter ended April 2, 2022.
-
Iridex to Report First Quarter 2022 Financial Results on May 12, 2022
4/28/2022
Iridex Corporation announced the Company will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 12, 2022.
-
Iridex Announces the Appointment of Beverly Huss to its Board of Directors
3/21/2022
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022.
-
Iridex Announces Fourth Quarter and Full Year 2021 Financial Results
3/10/2022
Iridex Corporation reported financial results for the fourth quarter and year ended January 1, 2022.
-
Iridex to Present at the 34th Annual Roth Conference
3/8/2022
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company plans to participate in the upcoming 34th Annual Roth Conference.
-
Iridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
2/24/2022
Iridex Corporation announced the Company will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, March 10, 2022.
-
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021
1/11/2022
Iridex Corporation provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 1, 2022.
-
Iridex to Present at the 2021 Stifel Virtual Healthcare Conference
11/12/2021
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company plans to participate in the upcoming 2021 Stifel Virtual Healthcare Conference.
-
Iridex Announces Third Quarter 2021 Financial Results
11/11/2021
Iridex Corporation reported financial results for the third quarter ended October 2, 2021.
-
Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting
11/6/2021
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announces that an international consensus panel of ten glaucoma experts will discuss MicroPulse Transscleral Laser Therapy and their conclusions for proper dosing and patient selection on November 6 at 10:00am PT/ 1:00pm ET.
-
Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021
10/28/2021
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021.
-
Iridex to Present at the Lytham Partners Fall 2021 Investor Conference
9/30/2021
Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company plans to participate in the upcoming Lytham Partners Fall 2021 Investor Conference.
-
Iridex Announces Second Quarter 2021 Financial Results
8/12/2021
Iridex Corporation reported financial results for the second quarter ended July 3, 2021.